Terug naar eerste hoofdstuk

• Aaby, P., et al., Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ, 1993. 307(6915): p. 1308-11 Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. (nih.gov)
• Amirthalingam, G., et al. (2022). Optimisation of timing of Maternal Pertussis Immunisation from 6 years of post-implementation surveillance data in England.  Clin Infect Dis. 2023 Feb 8;76(3):e1129-e1139. 
• Bautista-Lopez, N., et al., Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine, 2000. 18(14): p. 1393-401 https://www.ncbi.nlm.nih.gov/pubmed/10618537
• Benfield, T., Rämet M., Valentini P., et al. “Safety, Tolerability, and Immunogenicity of V114 Pneumococcal Vaccine Compared with PCV13 in a 2+1 Regimen in Healthy Infants: A Phase III Study (PNEU-PED- EU Europese unie (Europese unie) (Europese unie)-2).” Vaccine, vol. 41, no. 15, Apr. 2023, pp. 2456–65. DOI.org (Crossref), https://doi.org/10.1016/j.vaccine.2023.02.041.
• Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019;2019.
• Beyea SC, Nicoll LH. Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure. Appl Nurs Res. 1995 Feb;8(1):23-33. doi: 10.1016/s0897-1897(95)80279-7. PMID: 7695353.
• Bili, A., Dobson S., Quinones J., et al. “A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Interchangeability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, and PCV13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION).” Vaccine, vol. 41, no. 3, Jan. 2023, pp. 657–65. DOI.org (Crossref), https://doi.org/10.1016/j.vaccine.2022.10.072.
• Blyth, C.C., Jayasinghe, S., Andrews R.M. “A Rationale for Change: An Increase in Invasive Pneumococcal Disease in Fully Vaccinated Children.” Clinical Infectious Diseases, June 2019, p. ciz493. DOI.org (Crossref), https://doi.org/10.1093/cid/ciz493.
• Bont de EGPM, Brand PLP, Dinant GJ, van Well, Cals Wel of geen paracetamol bij kinderen met koorts? Wel of geen paracetamol bij kinderen met koorts? [Risks and benefits of paracetamol in children with fever] — Maastricht University
• Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol.  s2018;47:42-58.
• Brown GC, Volk VK, Gottshall RY, Kendrick PL, Anderson HD. Responses of infants to  DTP Difterie, Tetanus en Poliomyelitis (Difterie, Tetanus en Poliomyelitis) vaccine used in nine injection schedules. Public Health Rep. 1964;79:585-602.
• Bühler S., Eperon G., Ribi C., Kyburz D., Van Gompel F., Visser L.G. et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly. 2015 Jul 28;145:w14159. doi: 10.4414/smw.2015.14159. eCollection 2015. PMID: 26218860
• Buijs SC & Boersma B. Cardiorespiratoire verstoringen na 1e vaccinatie bij prematuur geboren kinderen, een prospectief cohortonderzoek. Nederlands Tijdschrift voor Geneeskunde 2012, 156:3797 www.ntvg.nl/artikelen/cardiorespiratoire-verstoringen-na-1e-vaccinatie-bij-prematuur-geboren-kinderen
• Burgmeijer R, Hoppenbrouwers K, van Gompel F. Handboek vaccinaties: Deel A en B Gorcum, 2de herziene druk 2011.
• Byrne, L., et al. (2017).  Hospitalisation of preterm infants with pertussis in the context of a maternal vaccination programme in England - PubMed (nih.gov)
• Campbell H, Gupta S, Dolan GP, Kapadia SJ, Kumar Singh A, Andrews N, et al. Review of vaccination in pregnancy to prevent pertussis in early infancy J Med Microbiol. 2018;67(10):1426-56.
• Chen RT, Clark TA, Halperin SA. The yin and yang of Paracetamol and paediatric immunizations. Lancet 2009, 374:1305-06.
• Clifford V, Crawford NW, Royle J, et al. Recurrent apnoea post immunisation: Informing reimmunisation policy. Vaccine 2011;29:5681-7.
• Croce E., Hatz C., Jonker E.F., Visser L.G., Jaeger V.K., Bühler S. Safety of live vaccinations on  immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine. 2017;.35(9):1216-26. 
• Das RR, Panigrahi I, Naik SS. The effect of prophylactic antipyretic administration on post-vaccination adverse reactions and antibody response in children: a systematic review.  PLoS One. 2014 Sep 2;9(9):e106629.
• De Greeff SC1, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, Notermans DW, Elvers LH, Schellekens JF, de Melker HE, Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010 May 15;50(10):1339-45 doi: 10.1086/652281 
• De Groot, R, T. Oomen, G. Vermeulen, J.A. van Vliet. Handhygiëne in de jeugdgezondheidszorg, ook bij het vaccineren? Infectieziekten Bulletin, maart 2014.
• De Serres, G., et al., Effectiveness of vaccination at 6 to 11 months of age during an outbreak of measles. Pediatrics, 1996. 97(2): p. 232-5.
• De Serres, G., et al., Higher risk of measles when the first dose of a 2-dose schedule of measles vaccine is given at 12-14 months versus 15 months of age. Clin Infect Dis, 2012. 55(3): p. 394-402 .
• De Serres, G., et al., Largest measles epidemic in North America in a decade-Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events. J Infect Dis, 2013. 207(6): p. 990-8. 
• DeSilva M, Vazquez-Benitez G, Nordin JD, Lipkind HS, Klein NP, Cheetham TC, et al., Maternal DTPa-HBV-IPV/Hib vaccine against invasive Haemophilus influenzae type b disease in the Netherlands (2003-16): a case-control study. Lancet Infect Dis. 2018.
• Doedée AM, Boland GJ, Pennings JL, de Klerk A, Berbers GA, van der Klis FR, de Melker HE, van Loveren H, Janssen R. Effects of prophylactic and therapeutic paracetamol treatment during vaccination on hepatitis B antibody levels in adults: two open-label, randomized controlled trials. PLoS One. 2014 Jun 4;9(6):e98175.
• Estívariz CF, Pallansch MA, Anand A, Wassilak SGF, Sutter RW, Wenger JD, Orenstein WA. Poliovirus vaccination options for achieving eradication and securing the endgame. Current opinion in Virology. 2013; 3(3):309-315.
• Flatz-Jequier A, Posfay-Barbe KM, Pfister RE, Siegrist CA. Recurrence of cardiorespiratory events following repeat DTaP-based combined immunization in very low birth weight premature infants. The Journal of pediatrics 2008;153:429-31.
• Furck AK, Richter JW, Kattner E. Very low birth weight infants have only few adverse events after timely immunization. Journal of perinatology 2010, 30:118-121 Heath 2012). 
• Furck Block, S.L., et al., Immunogenicity and Safety of a 3- and 4-dose Vaccination Series of a Tdap vaccination and risk of infant morbidity. Vaccine. 2017;35(29):3655-60.
• Gans, H., et al., Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months.  J Infect Dis, 2001. 184(7): p. 817-26.
• Gans, H., et al., Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine, 2003. 21(24): p. 3398-405.
• Gans, H.A., et al., Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA, 1998. 280(6): p. 527-32.
• Gans, H.A., et al., Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis, 2013. 207(4): p. 574-82.
• Garner Julia & the Members of the Injection Safety Best Practices Development Group Objective Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections 2003.
• Gezondheidsraad 2007 De toekomst van het Rijksvaccinatieprogramma.
• Gezondheidsraad 2008 Vaccinatie tegen baarmoederhalskanker.
• Gezondheidsraad 2009 Algemene vaccinatie tegen hepatitis B herbeoordeeld.
• Gezondheidsraad 2010 Vaccinatie van zuigelingen tegen pneumokokkeninfecties.
• Gezondheidsraad 2012 Het Rijksvaccinatieprogramma in Caribisch Nederland.
• Gezondheidsraad 2013 Vaccinatie van zuigelingen tegen pneumokokkeninfecties.
• Gezondheidsraad 2015 Vaccinatie tegen kinkhoest: doel en strategie.
• Gezondheidsraad 2018 Vaccinatieschema zuigelingen na maternale kinkhoestvaccinatie.
• Gezondheidsraad 2019 Vaccinatie tegen HPV.
• Gezondheidsraad 2020 Vaccinatie tegen waterpokken.
• Gill, C.J., et al., Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents. Hum Vaccin, 2010. 6(11): p. 881-7.
• Goldblatt D, Southern J, Ashton L, et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J. 2010;29(5):401-405.
• Gonçalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014;18(6):651-9.
• Götestam Skorpen C., Hoeltzenbein M., Tincani A., Fischer-Betz R., Elefant E., Chambers C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.
• Harder T, Wichmann O, Klug SJ, van der Sande MAB, Wiese-Posselt M. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med. 2018;16(1):110.
• Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196-204.
• Heijstek M.W., Kamphuis S., Armbrust W., Swart J., Gorter S., De Vries L.D. et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial. JAMA. 2013;309(23):2449-56.
• Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM, Berbers GA, van der Klis FR, Wulffraat NM. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014 Aug;73(8):1500-7. doi: 10.1136/annrheumdis-2013-203429. Epub 2013 May 30. PMID: 23723319.
• Hilgersom JA,   AAW Algemene arbeidsongeschiktheidswet (Algemene arbeidsongeschiktheidswet) (Algemene arbeidsongeschiktheidswet) (Algemene arbeidsongeschiktheidswet)van Boekel, HC Rümke. 'Aanvallen na vaccinatie van zuigelingen en peuters’. Tijdschr Jeugdgezondheidsz (2017) 49:2–7 DOI 10.1007/s12452-016-0092-4 Januari 2017 https://apps.who.int/iris/bitstream/10665/255353/1/WER9219.pdf.
• Hoefnagel J., Sonder G., Visser L. Afweeronderdrukker beperkt vaccinatieopties. Medisch Contact. 2016, 25.
• Hutchins, S.S., et al., Evaluation of an early two-dose measles vaccination schedule. Am J Epidemiol, 2001. 154 (11): p. 1064-71.
• Hutin Y, Hauri A, Chiarello L, Catlin M, Stilwell B, Ghebrehiwet T, Garner J; Injection Safety Best Practices Development Group. Best infection control practices for intradermal, subcutaneous, and intramuscular needle injections. Bull World Health Organ. 2003;81(7):491-500. Epub 2003 Sep 3. PMID: 12973641; PMCID: PMC2572501.
• IARC HPV Humaan Papillomavirus (Humaan Papillomavirus ) Working Group. Primary end-points for prophylactic HPV vaccine trials. IARC Working Group Reports, No. 7. Lyon: International Agency for Research on Cancer; 2014.
• Johnston, W., et al., Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age. Pediatr Infect Dis J, 2016. 35(1): p. e19-27.
• Julsgaard, M, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151: 110-9. 10.1053/j.gastro.2016.04.002
• Kamolratanakul S, & Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines, 2021;9(12), 1413.
• Kaninda AV et al., Measles vaccine effectiveness in standard and early immunization strategies, Niger, 1995
• Keller-Stanislawski B, Englund JA, Kang G, Mangtani P, Neuzil K, Nohynek H, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014;32(52):7057-64.
• Kemmeren JM, de Melker HE, The National Immunisation Programme in the Netherlands, 2020.
• King AJ, van Gorkom T, van der Heide HG, Advani A, van der Lee S. Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift? BMC Genomics. 2010 Jan 26;11:64 .
• Klein, N.P., et al., Five-year Antibody Persistence and Booster Response After 1 or 2 Doses. Infect Dis J, 2016. 35(6): p. 662-72.
• Knuf, M., et al., A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine, 2010. 28(3): p. 744-53.
• Lafeber Prospectief Vaccinatie Onderzoek. Antistofrespons bij kinderen in het Rijksvaccinatieprogramma 2002.
• Lalwani Sanjay, Sharad Agarkhedkar, Nithya Gogtay, Sonali Palkar, Shalaka Agarkhedkar, Urmila Thatte, Hoshang Vakil, Rekha Jonnalagedda, Paola Pedotti, Margaret Hoyle, Chiranjiwi Bhusal, Ashwani Arora, Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years. International Journal of Infectious Diseases, Volume 38, 2015, Pages 36-42.
• LCR-protocol Stollingsstoornissen 2015.
• Ling, J, Koren G, Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines 2016;15(2): 239-56.
• Lupinacci, R., Rupp R., Wittawatmongkol O., et al. “A Phase 3, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-Dose Regimen of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Healthy Infants (PNEU-PED).” Vaccine, vol. 41, no. 5, Jan. 2023, pp. 1142–52. DOI.org (Crossref), https://doi.org/10.1016/j.vaccine.2022.12.054.
• Macartney, K.K., Chiu, C., Georgousakis, M. et al. Safety of Human Papillomavirus Vaccines: A Review. Drug Saf 36, 393–412 (2013). https://doi.org/10.1007/s40264-013-0039-5.
• Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781-9.
• Mahadevan U., Cucchiara S., Hyams J.S., Steinwurz F., Nuti F., Travis S.P. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: Pregnancy and Pediatrics. American Journal of Gastroenterology, February 2011, Vol. 106, Issue 2: 214-223
• Mahadevan, U, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11(3): 286-92.
• Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. American journal of reproductive immunology.
• Markowitz, L.E., et al., Immunization of six-month-old infants with different doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. 
• Markowitz, L.E., et al., Persistence of measles antibody after revaccination. J Infect Dis, 1992. 166(1): p. 205.
• Meinus C, Schmalisch G, Hartenstein S, Proquitté H, Roehr CC. Adverse cardiorespiratory events following primary vaccination of very low birth weight infants. J Pediatr (Rio J). 2012 Mar-Apr;88(2):137. 
• Mialet-Marty T, Beuchee A, Ben Jmaa W, et al. Possible predictors of cardiorespiratory events after immunization in preterm neonates. Neonatology 2013;104:151-5.
• Multidisciplinaire richtlijn Antitrombotisch beleid.
• Murphy, M.D., et al., Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics, 1984. 74(1): p. 90-3.
• Naleway AL, Kurosky S, Henninger ML, Gold R, Nordin JD, Kharbanda EO, Irving S, Craig Cheetham T, Nakasato C, Glanz JM, Hambidge SJ, Davis RL, Klein NP, McCarthy NL, Weintraub. Vaccinations given during pregnancy 2002-2009: a descriptive study. Am J Prev Med. 2014 Feb;46(2):150-7
• Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013;381(9862):214-222
• Peltola H. Worldwide Haemophilus influenzae Type b Disease at the Beginning of the 21st Century: Global Analysis of the Disease Burden 25 Years after the Use of the Polysaccharide Vaccine and a Decade after the Advent of Conjugates. Clinical Microbiology Reviews. 2000;13(2):302-317.
• Nicoll LH, Hesby A. Intramuscular injection: an integrative research review and guideline for evidence-based practice. Appl Nurs Res. 2002 Aug;15(3):149-62. doi: 10.1053/apnr.2002.34142. PMID: 12173166.
• Pichichero, M. E. (2014). Challenges in vaccination of neonates, infants and young children. Vaccine 32(31): 3886-3894.
• Plotkin S, Orenstein W, Offit P, Edwards KM, Plotkin's Vaccines 7th edition 2017
• Plotkin, S., et al. (2018). Vaccines.
• Porter, J.D., et al., Measles outbreaks in the Mozambican refugee camps in Malawi: the continued need for an effective vaccine. Int J Epidemiol, 1990. 19(4): p. 1072-7.
• Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. Phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine.
• Prymula R, Siegrist C, Chlibek R et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label randomised controlled trials. Lancet 2009, 374:1339–50 .
• Puthanakit T., Schwarz T., Esposito S., Frenette L., McNeil S., Rheault P.6 Horn M., Poncelet S., Suryakiran P., Hezareh M., Thomas F., Descamps D., Struyf F. Immune responses to a 2-dose schedule of the HPV-16/18 as04-adjuvanted vaccine in girls (9-14) versus 3 doses in women (1525): a randomised trial Chulalongkorn University, Faculty of Medicine, Department of Pediatrics, Division of Infectious Diseases, Bangkok 2013.
• Puthanakit, T., Huang, L.-M., Chiu, C.-H., Tang, R.-B., Schwarz, T., Esposito, S., De Simoni, S. (2016, August 15). Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9–14 Years Versus a 3-Dose Regimen in Women Aged 15–25 Years. The Journal of Infectious Diseases, Volume 214(Issue 4), 525-536.
• RIVM Rijksinstituut voor Volksgezondheid en Milieu (Rijksinstituut voor Volksgezondheid en Milieu)-notitie: Nynke Rots, Nicoline van der Maas, Hans van Vliet, Laura Antonise-Kamp; Timing van vaccinatie tegen kinkhoest tijdens de zwangerschap. RIVM 3 september 2019.
• Romanowski B, Schwarz T, Ferguson L, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Suryakiran P, Thomas F, Struyf F. Immune response to the HPV-16/18 as04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination 2013.
• Romanowski, B., Schwarz, T., Ferguson, L., Peters, K., Dionne, M., Schulze, K., Descamps, D. (2011, Dec 7). Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin, 1374-86.
• Rümke, Postvaccinatie verschijnselen: prikplaatsreacties en reactogeniciteit (2016) 48 :50–56 DOI 10.1007/s12452-016-0060-z. Mei 2016.
• Rümke HC, Kant AC.  RVP Rijksvaccinatieprogramma (Rijksvaccinatieprogramma)-vaccinaties: melden van bijwerkingen. Tijdschr Jeugdgezondheidsz (2014) jaargang 46 nr 4: 75-80.
• Rümke HC. Samenstelling van vaccins en bijwerkingen Tijdschr Jeugdgezondheidsz (2016): 1-8 DOI 10.1007/ s12452-016-0087-1. 11-11-2016.
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 Suppl 5(0 5):F123-38.
• Schurink, T., & de Melker, H. (2017). HPV vaccination: Background information for the Dutch Health Council. Bilthoven: RIVM. Opgehaald van https://www.rivm.nl/publicaties/hpv-vaccination-background-information-for-dutch-health-council.
• Shasby, DM. et al., Epidemic measles in a highly vaccinated population. N Engl J Med, 1977.296(11):p. 585-9. 
• Skibinski DAG, Baudner BC, Singhet M et al. Combination Vaccines. J Glob Infect Dis 2011, 3:63-72.
• Skinner SR, Apter D, De Carvalho N, Harper DM, Konno R, Paavonen J, et al. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15(3):367-87.
• Spijkerman J, Veenhoven RH, Wijmenga-Monsuur AJ, Elberse KE, van Gageldonk PG, Knol MJ, de Melker HE, Sanders EA, Schouls LM, Berbers GA. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial. JAMA. 2013 Sep 4;310(9):930-7. doi: 10.1001/jama.2013.228052
• Toussirot E., Bereau M. Vaccination and Induction of Autoimmune Diseases. Inflamm Allergy Drug Targets. 2015; 14(2): 94-8.
• Tunis, M., Deeks, S., & (NACI), N. A. (2016). Summary of the National Advisory Committee on Immunization's updated recommendations on human papillomavirus (HPV) vaccines: Nine-valent human papillomavirus (HPV) of minimum intervals between doses in the HPV immunization schedule. Canada Communicable Disease Report, 149-151. doi:10.14745/ccdr.v42i07a03
• Whelan J, Hahné S, Guy A.M. Berbers, Fiona van der Klis, Yvonne Wijnands & Hein Boot, Human Vaccines & Immunotherapeutics ISSN: 2164-5515 Immunogenicity of a hexavalent vaccine coadministered with 7-valent pneumococcal conjugate vaccine.  Findings from the National Immunisation Programme in the Netherlands.
• WHO Renewed commitment to elimination of measles and rubella and prevention of congenital rubella syndrome by 2015 and Sustained support for polio-free status in the WHO European Region 2010.
• WHO. (2019). "Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations." Vaccine 37(2): 223-225.
• WHO. (2015) ''Reducing pain at the time of vaccination: WHO position paper - September 2015. '' Wkly Epidemiol Rec 90(39): 505-510.
• WHO. (2022). 11 April 2022.
• Wieringa JW, Driessen GJ, van der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterology & Hepatology 2018;12(8):811-8.
• Wijhe, Maarten van, Melker Hester de, Postma Maarten, Wallinga Jacco, Effect of vaccination programmes on mortality burden among children and young adults in the Netherlands during the 20th century: a historical analysis. 9 February 2016 The Lancet.
• Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr. 1979 Jun;94(6):865-9. doi: 10.1016/s0022-3476(79)80203-6. PMID: 448525.
• Woudenberg, Effectiveness of Early Measles, Mumps, and Rubella Vaccination Among 6-14Month-Old Infants During an Epidemic in the Netherlands: An Observational Cohort Study.  J Infect Dis.
• Zhang J, Qin Z, Lou C, Huang J, Xiong Y. The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis. Public Health. 2021;196:165-71.
• Zhao S, Hu S, Xu X, Zhang X, Pan Q, Chen F, et al. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial. BMC Infect Dis. 2020;20(1):846